A Systematic Review of Naldemedine and Naloxegol for the Treatment of Opioid-Induced Constipation in Cancer Patients
Pharmacy · 06.03.2024 · 12 (2) · 48
DOI: 10.3390/pharmacy12020048 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacy, online erschienen am 06.03.2024. Verfasst von Ursula K Braun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Rehabilitation & Extended Care Line, Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael E. DeBakey VA medical center in Houston, TX.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Opioid-induced constipation (OIC) is a pervasive and distressing side effect of chronic opioid therapy in patients with cancer pain, significantly impacting their quality of life. Peripherally acting μ-opioid receptor antagonists (PAMORAS) were developed for treatment-resistant OIC but most studies were conducted with non-cancer patients. Objective: to discuss two oral formulations of PAMORAs, naldemedine and naloxegol, and to review available evidence of the effectiveness of these drugs for OIC in cancer patients. Methods: a comprehensive search to identify primary literature for either naldemedine or naloxegol for OIC in cancer patients.
Results
Only three prospective randomized, double-blind, placebo-controlled clinical trials for naldemedine enrolling cancer patients were identified; the results of a subgroup analysis of two of those studies and two non-interventional post marketing surveillance studies of these trials are also reported here. For naloxegol, only two randomized controlled trials were identified; both were unsuccessful in enrolling sufficient patients. An additional four prospective non-interventional observational studies with naloxegol were found that enrolled cancer patients. There were significantly higher rates of responders in the PAMORA groups than in the placebo groups. The most common side effect for both PAMORAs was diarrhea.
Limitations
All studies were industry-funded, and given that only three trials were randomized controlled studies, the overall quality of the studies was lacking.
Conclusion
Naldemedine or naloxegol appeared safe and useful in the treatment of OIC in cancer patients and may improve their quality of life. Larger-scale randomized placebo-controlled studies of PAMORAs in cancer patients would strengthen existing evidence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rehabilitation & Extended Care Line, Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA.
- Section of Geriatrics & Palliative Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
- Office of Connected Care, Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA.
ORCID-Profile: Mary A Garcia
Förderung
- Michael E. DeBakey VA medical center in Houston, TX
Zitieren
APA
Braun, U. K., Jackson, L. K., Garcia, M. A., & Imam, S. N. (2024). A Systematic Review of Naldemedine and Naloxegol for the Treatment of Opioid-Induced Constipation in Cancer Patients. Pharmacy, 12(2), 48. https://doi.org/10.3390/pharmacy12020048
Vancouver
Braun UK, Jackson LK, Garcia MA, Imam SN. A Systematic Review of Naldemedine and Naloxegol for the Treatment of Opioid-Induced Constipation in Cancer Patients. Pharmacy. 2024;12(2):48. doi:10.3390/pharmacy12020048
BibTeX
@article{Braun2024,
author = {Braun, Ursula K and Jackson, Leanne K and Garcia, Mary A and Imam, Syed N},
title = {A Systematic Review of Naldemedine and Naloxegol for the Treatment of Opioid-Induced Constipation in Cancer Patients},
journal = {Pharmacy},
year = {2024},
volume = {12},
number = {2},
pages = {48},
doi = {10.3390/pharmacy12020048}
}
EUVIMED